^
No biomarker
Pancreatic Ductal Adenocarcinoma
SBP-101
Sensitive: B - Late Trials
No biomarker
Pancreatic Ductal Adenocarcinoma
gemcitabine
Sensitive: B - Late Trials
No biomarker
Pancreatic Ductal Adenocarcinoma
gemcitabine + capecitabine
Sensitive: B - Late Trials
CCL11 overexpression
Pancreatic Ductal Adenocarcinoma
tertomotide
Sensitive: B - Late Trials
No biomarker
Pancreatic Ductal Adenocarcinoma
CEND-1
Sensitive: B - Late Trials
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Sensitive: B - Late Trials
KRAS wild-type
Pancreatic Ductal Adenocarcinoma
5-fluorouracil + oxaliplatin
Sensitive: B - Late Trials
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
ATM mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C1 - Off-label
KRAS mutation
Pancreatic Ductal Adenocarcinoma
pembrolizumab + trametinib
Sensitive: C2 – Inclusion Criteria
HGF-H
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Resistant: C3 – Early Trials
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
nivolumab
Sensitive: C3 – Early Trials
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
ipilimumab
Sensitive: C3 – Early Trials
MSI-L/dMMR
Pancreatic Ductal Adenocarcinoma
pembrolizumab
Sensitive: C3 – Early Trials
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
BRCA1 mutation + BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
FANCF mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
MSH2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Sensitive: C3 – Early Trials
DDR
Pancreatic Ductal Adenocarcinoma
olaparib
Sensitive: C3 – Early Trials
C3M/PRO-C3 ratio elevation
Pancreatic Ductal Adenocarcinoma
PEGPH20
Sensitive: C3 – Early Trials
PALB2 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
BRCA2 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
BRCA1 mutation
Pancreatic Ductal Adenocarcinoma
cisplatin + gemcitabine
Sensitive: C3 – Early Trials
GATA6 underexpression
Pancreatic Ductal Adenocarcinoma
leucovorin calcium
Resistant: C3 – Early Trials
GATA6 underexpression
Pancreatic Ductal Adenocarcinoma
5-fluorouracil
Resistant: C3 – Early Trials
GATA6 expression
Pancreatic Ductal Adenocarcinoma
gemcitabine
Resistant: C3 – Early Trials
LAMC2 overexpression
Pancreatic Ductal Adenocarcinoma
gemcitabine
Resistant: C3 – Early Trials
ATM mutation
Pancreatic Ductal Adenocarcinoma
durvalumab + gemcitabine + CP-675206
Sensitive: C3 – Early Trials
ARID1A mutation
Pancreatic Ductal Adenocarcinoma
Immunotherapy
Sensitive: C3 – Early Trials
PD-L1 expression
Pancreatic Ductal Adenocarcinoma
pembrolizumab + trametinib
Sensitive: C3 – Early Trials
GATA6 underexpression
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Resistant: C3 – Early Trials
MUC1 underexpression
Pancreatic Ductal Adenocarcinoma
gemcitabine
Sensitive: C3 – Early Trials
CLDN18.2 positive
Pancreatic Ductal Adenocarcinoma
CT041
Sensitive: C3 – Early Trials
CAV1 overexpression
Pancreatic Ductal Adenocarcinoma
gemcitabine + albumin-bound paclitaxel
Resistant: C3 – Early Trials
MAP2K1 mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
PD-L1 overexpression
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
MAP2K2 mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
PIK3CA mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
RNF43 mutation
Pancreatic Ductal Adenocarcinoma
avelumab + binimetinib
Sensitive: C3 – Early Trials
KRAS G12C
Pancreatic Ductal Adenocarcinoma
MRTX849
Sensitive: C3 – Early Trials
TP53 mutation + KRAS mutation
Pancreatic Ductal Adenocarcinoma
PD1 inhibitor
Sensitive: C3 – Early Trials
KRAS mutation + PD-L1 expression
Pancreatic Ductal Adenocarcinoma
pembrolizumab + trametinib
Sensitive: C3 – Early Trials
ATP1B1-NRG1 fusion
Pancreatic Ductal Adenocarcinoma
afatinib
Sensitive: C4 – Case Studies
APP-NRG1 fusion
Pancreatic Ductal Adenocarcinoma
afatinib
Sensitive: C4 – Case Studies
FGFR1 T141R
Pancreatic Ductal Adenocarcinoma
crizotinib
Resistant: C4 – Case Studies
FGFR1 T141R
Pancreatic Ductal Adenocarcinoma
alectinib
Sensitive: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
Pancreatic Ductal Adenocarcinoma
lorlatinib
Sensitive: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
Pancreatic Ductal Adenocarcinoma
FOLFIRINOX
Resistant: C4 – Case Studies
PPFIBP1-ALK translocation + ALK G1202R + ALK V1180L
Pancreatic Ductal Adenocarcinoma
alectinib
Resistant: C4 – Case Studies
MSI-H/dMMR + TMB-H + PD-L1 overexpression
Pancreatic Ductal Adenocarcinoma
pembrolizumab
Sensitive: C4 – Case Studies
BRCA1 mutation + TMB-H
Pancreatic Ductal Adenocarcinoma
pembrolizumab + olaparib
Sensitive: C4 – Case Studies
BRAF V600E
Pancreatic Ductal Adenocarcinoma
trametinib + vemurafenib
Sensitive: C4 – Case Studies
TLE2 overexpression
Pancreatic Ductal Adenocarcinoma
gemcitabine
Sensitive: D – Preclinical
KRAS mutation
Pancreatic Ductal Adenocarcinoma
BAL3833
Sensitive: D – Preclinical
ANIB1 overexpression
Pancreatic Ductal Adenocarcinoma
GANT1
Sensitive: D – Preclinical
ANIB1 overexpression
Pancreatic Ductal Adenocarcinoma
GANT61
Sensitive: D – Preclinical
ANIB1 overexpression
Pancreatic Ductal Adenocarcinoma
Hedgehog cell-signalling pathway inhibitor
Sensitive: D – Preclinical
ANIB1 overexpression
Pancreatic Ductal Adenocarcinoma
cyclopamine
Sensitive: D – Preclinical
ANIB1 overexpression
Pancreatic Ductal Adenocarcinoma
sonidegib
Sensitive: D – Preclinical
ASS1 underexpression
Pancreatic Ductal Adenocarcinoma
panobinostat + pegargiminase
Sensitive: D – Preclinical
TMB-L
Pancreatic Ductal Adenocarcinoma
trametinib + Torin1
Sensitive: D – Preclinical
MUC1 overexpression
Pancreatic Ductal Adenocarcinoma
BBI608
Sensitive: D – Preclinical
CDKN2A deletion
Pancreatic Ductal Adenocarcinoma
BET inhibitor + CDK inhibitor
Sensitive: D – Preclinical
TP53 mutation
Pancreatic Ductal Adenocarcinoma
FL118
Sensitive: D – Preclinical
DDX5 overexpression
Pancreatic Ductal Adenocarcinoma
FL118
Sensitive: D – Preclinical
GLI1 expression
Pancreatic Ductal Adenocarcinoma
sonidegib
Sensitive: D – Preclinical
SIRT1 overexpression
Pancreatic Ductal Adenocarcinoma
gefitinib
Sensitive: D – Preclinical
BRCA mutation
Pancreatic Ductal Adenocarcinoma
PARP inhibitor
Sensitive: D – Preclinical
KRAS G12D + Chr del(9)(p21)
Pancreatic Ductal Adenocarcinoma
palbociclib
Resistant: D – Preclinical
CD276 expression
Pancreatic Ductal Adenocarcinoma
B7-H3-targeted antibody-drug conjugate
Sensitive: D – Preclinical
SLC3A2-NRG1 fusion
Pancreatic Ductal Adenocarcinoma
MM-121
Sensitive: D – Preclinical
ATP1B1-NRG1 fusion
Pancreatic Ductal Adenocarcinoma
MM-121
Sensitive: D – Preclinical
KRAS G12C
Pancreatic Ductal Adenocarcinoma
sotorasib + selinexor
Sensitive: D – Preclinical
KRAS G12C
Pancreatic Ductal Adenocarcinoma
selinexor + MRTX1257
Sensitive: D – Preclinical
KRAS mutation
Pancreatic Ductal Adenocarcinoma
RMC-6236
Sensitive: D – Preclinical
MYC overexpression
Pancreatic Ductal Adenocarcinoma
WB100
Sensitive: D – Preclinical
KRAS mutation
Pancreatic Ductal Adenocarcinoma
ASN007 + ERAS-601
Sensitive: D – Preclinical
CDKN2A deletion
Pancreatic Ductal Adenocarcinoma
palbociclib + JQ-1
Sensitive: D – Preclinical
KRAS G12D
Pancreatic Ductal Adenocarcinoma
trametinib + BI-3406
Sensitive: D – Preclinical
KRAS G12D
Pancreatic Ductal Adenocarcinoma
MRTX1133 + BI 894999 + dBET6
Sensitive: D – Preclinical